gemcitabine + vinorelbine + eribulin + utidelone

This entry refers to an adaptive chemotherapy regimen consisting of gemcitabine, vinorelbine, eribulin, and utidelone, which is being evaluated by Sun Yat-sen University for the treatment of advanced breast cancer. Studied in a Phase 3 clinical trial (NCT05810311), this approach involves the selective use of these four cytotoxic agents, with treatment cycles and drug selection adapted based on patient response and progression following standard therapies. Gemcitabine is a nucleoside analog that inhibits DNA synthesis and ribonucleotide reductase; vinorelbine is a vinca alkaloid that inhibits microtubule polymerization; eribulin is a non-taxane microtubule dynamics inhibitor; and utidelone is an epothilone analog that stabilizes microtubules. The regimen aims to improve outcomes in patients with advanced disease by optimizing the timing and selection of these small molecule antineoplastics.

Other names

gemcitabinevinorelbineeribulinutidelone